GSK In China: 13 Years Later - Whistleblower Emails, a Sex Tape, and the Compliance Failures That Triggered a Global Bribery Probe

GSK In China: 13 Years Later – Whistleblower Emails, a Sex Tape, and the Compliance Failures That Triggered a Global Bribery Probe

April 9, 2026

Thirteen years after the GSK China scandal exploded onto the global stage, its lessons remain as urgent as ever for compliance professionals and business leaders. In this podcast series, we revisit the case not simply as corporate history, but as a living cautionary tale about culture, incentives, third parties, investigations, and governance. Each episode explores what went wrong, why it went wrong, and how those failures still echo in today’s compliance and ethics landscape. Join us as we unpack the scandal and draw practical lessons for building stronger, more resilient organizations. This episode dissects how an anonymous “GSK whistleblower” email campaign—culminating in a covertly filmed sex tape of China executive Mark Reilly—triggered a wider reckoning over alleged systemic bribery in GSK’s China business.

Drawing on reporting from MailOnline, The Wall Street Journal, The Sunday Times, and Time, it outlines claims of a £320m bribery budget routed through third-party travel agencies via fake or inflated medical conferences, with allegations extending to sexual favors, and how GSK initially treated the tape as a compartmentalized security/blackmail issue. GSK hired China-based investigators, Peter Humphrey and Yu Yingzeng, to identify the source; they failed and were arrested for privacy-law violations, as Chinese police opened a formal bribery probe that led to charges against Reilly and 45 others. The fallout expanded to the UK SFO and potential U.S. FCPA exposure via GSK’s NYSE listing, framed against pervasive surveillance risks in China and the dangers of “toothless” internal investigations.